THE ANALYSIS OF RASSF1A AND SEMA3B TUMOR SUPRESSOR GENES CPG-ISLANDS METHYLATION STATUS IN UVEAL MELANOMA PATIENTS

2018 ◽  
Vol 16 (1) ◽  
Author(s):  
S.V. Saakyan ◽  
A.Iu. Tsygankov ◽  
A.G. Amiryan ◽  
V.I. Loginov ◽  
A.M. Burdennyy
Keyword(s):  
Uveal Melanoma ◽  
Methylation Status ◽  
Cpg Islands ◽  
Tumor Supressor ◽  
Melanoma Patients

Methylation status of the p16 tumor-supressor and DAP-kinase genes in colon biopsies from normal and ulcerative colitis samples

2007 ◽  
Vol 45 (05) ◽  
Author(s):  
T Hevér-Pálfy ◽  
O Galamb ◽  
S Spisák ◽  
B Galamb ◽  
B Molnár ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Methylation Status ◽  
Tumor Supressor ◽  
Dap Kinase

scholarly journals Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

2021 ◽  
Vol 10 (8) ◽  
pp. 2618-2626
Author(s):  
Michael S. Sander ◽  
Igor Stukalin ◽  
Isabelle A. Vallerand ◽  
Siddhartha Goutam ◽  
Benjamin W. Ewanchuk ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Prognostic Index ◽  
Melanoma Patients

Cutaneous dysplastic naevi in uveal melanoma patients: markers for prognosis?

2000 ◽  
Vol 10 (1) ◽  
pp. 36-39 ◽  
Author(s):  
E. Tóth-Molnár ◽  
H. Hammer ◽  
J. Oláh
Keyword(s):  
Uveal Melanoma ◽  
Melanoma Patients

Aberrant Genes Promoter Methylation in Neural Crest-Derived Tumors

2012 ◽  
Vol 27 (4) ◽  
pp. 389-394 ◽  
Author(s):  
Annamaria La Torre ◽  
Lucia Anna Muscarella ◽  
Paola Parrella ◽  
Teresa Balsamo ◽  
Michele Bisceglia ◽  
...  
Keyword(s):  
Small Bowel ◽  
Neural Crest ◽  
Promoter Methylation ◽  
Methylation Status ◽  
Cpg Islands ◽  
Aberrant Methylation ◽  
Tumor Type ◽  
Epigenetic Landscape ◽  
Molecular Biomarker

Disturbances in the epigenetic landscape by aberrant methylation of CpG islands can lead to inactivation of cancer-related genes in solid tumors. We analyzed the promoter methylation status of 6 genes previously reported as cancer-specific methylated (MCAM, SSBP2, NISCH, B4GALT1, KIF1A and RASSF1A) in 38 neural crest-derived tumors by quantitative methylation-specific real-time PCR (QMSP). The results demonstrated that the determination of the methylation status of RASSF1A is able to distinguish between normal and tumor samples in cutaneous melanomas, lung carcinoids and small bowel carcinoids. MCAM methylation levels were significantly higher in lung carcinoids tumors (p=0.001), suggesting that this alteration may represent a molecular biomarker in this tumor type.

Possible Implications of MCAM Expression in Metastasis and Non-Metastatic of Primary Uveal Melanoma Patients

2009 ◽  
Vol 34 (11) ◽  
pp. 1004-1009 ◽  
Author(s):  
Julia Beutel ◽  
Jürgen Wegner ◽  
Rayime Wegner ◽  
Focke Ziemssen ◽  
Khaled Nassar ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Melanoma Patients

Genome-wide study on uveal melanoma patients finds association to DNA repair gene TDP1

2020 ◽  
Vol 30 (2) ◽  
pp. 166-172
Author(s):  
Hauke Thomsen ◽  
Subhayan Chattopadhyay ◽  
Per Hoffmann ◽  
Markus M. Nöthen ◽  
Helen Kalirai ◽  
...  
Keyword(s):  
Dna Repair ◽  
Uveal Melanoma ◽  
Repair Gene ◽  
Genome Wide ◽  
Dna Repair Gene ◽  
Melanoma Patients ◽  
Genome Wide Study

scholarly journals Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling

2020 ◽  
Vol 7 (1) ◽  
pp. 17-25 ◽  
Author(s):  
Amy C Schefler ◽  
Alison Skalet ◽  
Scott C N Oliver ◽  
John Mason ◽  
Anthony B Daniels ◽  
...  
Keyword(s):  
Gene Expression ◽  
Uveal Melanoma ◽  
Clinical Utility ◽  
Medical Oncology ◽  
Treatment Plan ◽  
Risk Class ◽  
Class 1 ◽  
Melanoma Patients ◽  
Metastatic Risk

Aim: The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results: A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion: Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.

Sign in / Sign up

Export Citation Format

Share Document